Ingredion Incorporated
Ingredion to Release 2025 Second Quarter Financial Results On August 1, 2025
Ingredion to Release 2025 Second Quarter Financial Results On August 1, 2025
WESTCHESTER, Ill., July 11, 2025 (GLOBE NEWSWIRE) -- Ingredion Incorporated (NYSE: INGR), a leading global provider of ingredient solutions to the food manufacturing industry, will release its second quarter 2025 financial results for the period ended June 30, 2025, before the market opens Friday, August 1, 2025.
Jim Zallie, president and chief executive officer and Jim Gray, executive vice president and chief financial officer, will host a conference call August 1 at 8 a.m. CT to discuss the Company's financial performance. The conference call and accompanying slide presentation will be webcast live at https://ir.ingredionincorporated.com/events-and-presentations. Participants are encouraged to log on to the webcast approximately 10 minutes before the start of the presentation. A replay of the presentation will be available on the Company's website.
ABOUT THE COMPANY
Ingredion Incorporated (NYSE: INGR) headquartered in the suburbs of Chicago, is a leading global ingredient solutions provider serving customers in more than 120 countries. With 2024 annual net sales of approximately $7.4 billion, the company turns grains, fruits, vegetables, and other plant-based materials into value-added ingredient solutions for the food, beverage, animal nutrition, brewing and industrial markets. With Ingredion's Idea Labs® innovation centers around the world and more than 11,000 employees, the company co-creates with customers and fulfills its purpose of bringing the potential of people, nature, and technology together to make life better. Visit ingredion.com for more information and the latest company news.
CONTACTS
Investors: Noah Weiss, 773-896-5242
Media: Rick Wion, 708-209-6323
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Novo Nordisk A/S31.8.2025 09:09:18 CEST | Press release
Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular diseas
Novartis Pharma AG30.8.2025 17:00:00 CEST | Press release
Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
F. Hoffmann-La Roche Ltd30.8.2025 16:30:00 CEST | Press release
Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension
CGTN30.8.2025 11:44:44 CEST | Pressemeddelelse
CGTN: Arven efter Flying Tigers fejres for at styrke det varige bånd mellem Kina og USA
Sanofi Winthrop Industrie29.8.2025 23:50:03 CEST | Press release
Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom